Page 138 - 2019_05-HaematologicaMondo-web

I. Spinello et al.
LSCs and a novel prognostic predictor in AML.20,34,47 Interestingly, in non-M3 AMLs a strong positive correla- tion was observed between CD147 and CD371 expres- sion. In this context, while a dedicated future study would shed light on the functional properties of LSCs of the frac- tions of (CD34+CD147+) and (CD34+CD371+CD147+) AML cells, our data suggest that CD147 is expressed in LSCs and may be a potential new prognostic marker in AML and a potential therapeutic target.
Taken together, our study demonstrates a pivotal role for CD147 in leukemic cell proliferation and indicates CD147 as a potential therapeutic target of AC-73 in AML.
Thus, targeting CD147 by using AC-73 or derivate mole- cules to induce autophagy or to inhibit the growth of leukemic clones, including LSCs, may be an effective option to improve leukemia treatment.
Acknowledgments
The authors would like to thank AM Cerio for assistance in cell cultures.
Funding
This study was supported by Istituto Superiore di Sanità (Rome, Italy).
References
1. Saultz JN, Garzon R. Acute Myeloid Leukemia: A Concise Review. J Clin Med. 2016;5:5(3).
2. Khaled S, Al Malki M, Marcucci G. Acute myeloid leukemia: biologic, prognostic, and therapeutic insights. Oncology (Williston Park). 2016;30(4):318-329.
3. Xiong L, Edwards CK 3rd, Zhou L. The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int J Mol Sci. 2014;15(10):17411-17441.
4. Somno A, Anuchapreeda S, Chruewkamlow N, Pata S, Kasinrerk W, Chiampanichayakul S. Involvement of CD147 on multidrug resistance through the regulation of P-glycoprotein expression in K562/ADR leukemic cell line. Leuk Res Rep. 2016;6:33-38.
5. Bai Y, Huang W, Ma LT, Jiang JL, Chen ZN. Importance of N-glycosylation on CD147 for its biological functions. Int J Mol Sci. 2014;15(4):6356-6377.
6. Grass GD, Dai L, Qin Z, Parsons C, Toole BP. CD147: regulator of hyaluronan signal- ing in invasiveness and chemoresistance. Adv Cancer Res. 2014;123:351-373.
7. Tang J, Guo YS, Zhang Y, et al. CD147 induces UPR to inhibit apoptosis and chemosensitivity by increasing the tran- scription of Bip in hepatocellular carcinoma. Cell Death Differ. 2012;19(11):1779-1790.
8. Gao H, Jiang Q, Han Y, Peng J, Wang C. shRNA-mediated EMMPRIN silencing inhibits human leukemic monocyte lym- phoma U937 cell proliferation and increas- es chemosensitivity to adriamycin. Cell Biochem Biophys. 2015;71(2):827-835.
9. Huang Z, Wang L, Wang Y, et al. Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells. J Oral Pathol Med. 2013;42(7):541-546.
10. Muramatsu T. Basigin (CD147), a multi- functional transmembrane glycoprotein with various binding partners. J Biochem. 2016;159(5):481-490.
11. Le Floch R, Chiche J, Marchiq I, et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of gly- colytic tumors. Proc Natl Acad Sci U S A. 2011;108(40):16663-16668.
12. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1
and MCT4, and facilitates their cell surface expression. EMBO J. 2000;19(15):3896- 3904.
13. Eliasson P, Jönsson JI. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol. 2010;222(1):17- 22.
14. Testa U, Labbaye C, Castelli G, Pelosi E. Oxidative stress and hypoxia in normal and leukemic stem cells. Exp Hematol. 2016;44(7):540-560.
15. FuJ,FuJ,ChenX,ZhangY,GuH,BaiY. CD147 and VEGF co-expression predicts prognosis in patients with acute myeloid leukemia. Jpn J Clin Oncol. 2010;40 (11):1046-1052.
16. Honnemyr M, Bruserud Ø, Brenner AK. The constitutive protease release by pri- mary human acute myeloid leukemia cells. J Cancer Res Clin Oncol. 2017; 143(10):1985-1998.
17. Zhu D, Wang Z, Zhao JJ, et al. The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015;21(6):572- 580.
18. Eichner R, Heider M, Fernández-Sáiz V, et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert anti- tumor activity and teratogenicity. Nat Med. 2016;22(7):735-743.
19. Panchabhai S, Schlam I, Sebastian S, Fonseca R. PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma. Leukemia. 2017;31(4):991-994.
20. van Rhenen A, van Dongen GA, Kelder A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110(7):2659-2666.
21. Fu ZG, Wang L, Cui HY, et al. A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells. Oncotarget. 2016;7(8):9429-9447.
22. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. Stat3 signaling in acute myeloid leukemia: ligand-dependent and - independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011;117(21):5701-5709.
23. Orsini M, Morceau F, Dicato M, Diederich M. Autophagy as a pharmacological target in hematopoiesis and hematological disor- ders. Biochem Pharmacol. 2018;152:347- 361.
24.
25.
26.
27.
28.
29.
30.
31. 32.
33.
34.
35.
Folkerts H, Hilgendorf S, Wierenga ATJ, et al. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia. Cell Death Dis. 2017;8(7):e2927. Jin J, Britschgi A, Schläfli AM, et al. Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored dur- ing AML Differentiation Therapy. Oxid Med Cell Longev. 2018;2018:1482795. Lo-Coco F, Cicconi L, Breccia M. Current standard treatment of adult acute promye- locytic leukaemia. Br J Haematol. 2016;172(6):841-854.
Goussetis DJ, Altman JK, Glaser H, McNeer JL, Tallman MS, Platanias LC. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem. 2010; 285(39):29989-29997.
Lulli V, Romania P, Riccioni R, et al. Transcriptional silencing of the ETS1 onco- gene contributes to human granulocytic differentiation. Haematologica. 2010; 95(10):1633-1641.
Spinello I, Quaranta MT, Paolillo R, et al. Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in nor- mal and leukemic monocytic cells: impact on response to chemotherapy. Haematologica. 2015;100(9):1160-1171. Labbaye C, Spinello I, Quaranta MT, et al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol. 2008;10(7):788-801.
Tanida I, Ueno T, Kominami E. LC3 and Autophagy. Methods Mol Biol. 2008; 445:77-88.
Benekli M, Xia Z, Donohue KA, et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 2002;99(1):252-257.
Lunghi P, Tabilio A, Dall'Aglio PP, et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia. 2003;17(9):1783-1793. Pelosi E, Castelli G, Testa U. Targeting LSCs through membrane antigens selec- tively or preferentially expressed on these cells. Blood Cells Mol Dis. 2015;55(4):336- 346.
Papayannopoulou T, Brice M. Integrin expression profiles during erythroid differ- entiation. Blood. 1992;79(7):1686-1694.
984
haematologica | 2019; 104(5)